Brainstorm Cell Therapeutics (NASDAQ:BCLI) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research report released on Friday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, Maxim Group upgraded shares of Brainstorm Cell Therapeutics from a hold rating to a buy rating and set a $2.00 price objective for the company in a research report on Thursday, July 11th.

Brainstorm Cell Therapeutics Price Performance

Shares of BCLI opened at $0.31 on Friday. The company has a market capitalization of $24.64 million, a P/E ratio of -0.97 and a beta of 0.37. Brainstorm Cell Therapeutics has a one year low of $0.13 and a one year high of $1.79. The business’s 50 day simple moving average is $0.34 and its 200-day simple moving average is $0.43.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last posted its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported ($0.04) EPS for the quarter, hitting analysts’ consensus estimates of ($0.04). During the same period last year, the business posted ($0.27) earnings per share. On average, sell-side analysts anticipate that Brainstorm Cell Therapeutics will post -0.19 EPS for the current fiscal year.

Hedge Funds Weigh In On Brainstorm Cell Therapeutics

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC bought a new stake in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned 0.12% of Brainstorm Cell Therapeutics at the end of the most recent quarter. Institutional investors own 14.33% of the company’s stock.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.